Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02717039 · ClinicalTrials.gov registry record
Pharmacogenomics of Heparin-Induced Thrombocytopenia
A clinical trial of Heparin-induced Thrombocytopenia, sponsored by University of Arizona.
- Recruiting
- Registry status
- 125
- Enrollment target
- 1
- Study location
NCT02717039 is a study of Heparin-induced Thrombocytopenia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 125 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02717039, a study of Heparin-induced Thrombocytopenia, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- 125 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prevent heparin use in people who will get HIT.
Conditions Studied
Interventions
- PROCEDURE Blood Draw
Study Locations (1)
Arizona
- Banner University Medical Center - Tucson - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-03 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02717039
The ClinicalTrials.gov registry entry for NCT02717039 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heparin-induced Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which Blood Draw is the first listed.
NCT02717039 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT02717039 about?
NCT02717039 is a clinical study titled "Pharmacogenomics of Heparin-Induced Thrombocytopenia". The purpose of this research is to identify genomic markers that can predict heparin-induced thrombocytopenia (HIT), which is a very serious side effect to heparin. Heparin is commonly used to prevent blood clots and the investigators may be able to identify genomic markers which can be used to prev...
What is the current status of trial NCT02717039?
This trial is currently recruiting. The enrollment target is 125 participants. The study started on 2016-03. Estimated completion is 2026-07.
What conditions does trial NCT02717039 study?
This clinical trial studies the following conditions: Heparin-induced Thrombocytopenia.
What interventions are being tested in trial NCT02717039?
The interventions under investigation include: Blood Draw (PROCEDURE).
Who is sponsoring clinical trial NCT02717039?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02717039 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heparin-induced Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects
COMPLETED · Phase 1
-
Anticoagulant Therapy With Bivalirudin in the Performance of Percutaneous Coronary Intervention in Patients With Heparin-Induced Thrombocytopenia (AT BAT, First Inning)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.